Impact of Obesity on Cancer Survivorship and the Potential Relevance of Race and Ethnicity

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (MLN)
Journal of the National Cancer Institute (Impact Factor: 12.58). 08/2013; 105(18). DOI: 10.1093/jnci/djt223
Source: PubMed


Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.

Full-text preview

Available from:
  • Source
    • "Greenberg et al. showed that symptoms of CRF increased during the course of RT in prostate cancer patients independent of depressive symptoms, but connected to changes in serum IL-1 levels [25]. This provides a plausible mechanism for adiposity augmenting treatmentinduced fatigue and increasing the risk for prolonged and more severe post-treatment CRF [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decade,significantdata haveshownthat obese men experience a survival detrimentafter treatment for prostate cancer. While methods to combat obesity are of utmost importance for the prostate cancer patient, newer data revealthe overall metabolic improvements that accompany increased activity levels and intense exercisebeyond weight loss. Along these lines, a plethora of data haveshown improvement in prostate cancer-specific outcomes after treatmentaccompanied with these activity levels. This review discusses the metabolic mechanismsin which increased activity levels and exercise can help improve both outcomes for men treated for prostate cancer while lowering the side effects of treatment.
    Full-text · Article · Jan 2016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Not Available.
    Full-text · Article · Oct 2013 · The Journal of Clinical Endocrinology and Metabolism
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is associated with an increased risk of breast cancer, and increased risk of recurrence in women who develop breast cancer. Evidence suggests that the risk of estrogen-receptor (ER)-positive breast cancer is increased in obese postmenopausal women, whereas in premenopausal women the risk of triple negative breast cancer is increased. Nonetheless, the presence of obesity at diagnosis, and possibly weight gain after diagnosis, may independently contribute to an individual's risk of recurrence of both pre- and postmenopausal breast cancer. Factors associated with adiposity that are likely contributing factors include hyperinsulinemia, inflammation, and relative hyperestrogenemia. Some studies suggest that some aromatase inhibitors may be less effective in obese women than lean women. Clinical trials have evaluated pharmacologic (eg, metformin) and dietary/lifestyle interventions to reduce breast cancer recurrence, although these interventions have not been tested in obese women who may be most likely to benefit from them. Further research is required in order to identify adiposity-associated factors driving recurrence, and design clinical trials to specifically test interventions in obese women at highest risk of recurrence.
    No preview · Article · Nov 2013 · Journal of Mammary Gland Biology and Neoplasia
Show more